Overview

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of RC48 (a HER2 antibody drug conjugate with MMAE payload) in combination with gemcitabine or capecitabine (with or without trastuzumab/inetetamab), for treatment of patients with HER2-positive advanced breast cancer (ABC) who have developed disease progression or intolerance to prior therapy with a topoisomerase I inhibitor antibody-drug conjugate (TOP1i-ADC).

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

Capecitabine
disitamab vedotin
Gemcitabine
Trastuzumab